CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Inc. COP Y/Y Annual
Syros Pharmaceuticals Inc   (SYRS)
Other Ticker:  
 
 

SYRS's Income from Cont. Operations Growth by Quarter and Year

Syros Pharmaceuticals Inc 's Income from Cont. Operations results by quarter and year




SYRS Income from Cont. Operations (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -4.77 -23.81 -30.13
III Quarter September - -30.25 -26.03 -19.49
II Quarter June - -34.48 -22.49 -17.20
I Quarter March -23.79 -25.15 -14.23 -17.23
FY   -23.79 -94.65 -86.56 -84.05



SYRS Income from Cont. Operations first quarter 2023 Y/Y Growth Comment
Syros Pharmaceuticals Inc in the first quarter 2023 recorded loss from continued operations of $ -23.79 millions.

According to the results reported in the first quarter 2023, Syros Pharmaceuticals Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Syros Pharmaceuticals Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the first quarter 2023.


SYRS Income from Cont. Operations ( Y/Y Growth %) 2023
 2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Syros Pharmaceuticals Inc 's first quarter 2023 Income from Cont. Operations $ -23.79 millions SYRS's Income Statement
Syros Pharmaceuticals Inc 's first quarter 2022 Income from Cont. Operations $ -25.15 millions Quarterly SYRS's Income Statement
New: More SYRS's historic Income from Cont. Operations Growth >>


SYRS Income from Cont. Operations (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -


Current SYRS Income Statement >> Back to SYRS Growth rate Comparisons >>


Income from Cont. Operations first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Syros Pharmaceuticals Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SYRS's I. Quarter Q/Q Income from Cont. Operations Comment
Recent results of -23.79 millions by Syros Pharmaceuticals Inc come out even less good if you take a look at -4.77 millions loss from continued operations in the fourth quarter.

Within Major Pharmaceutical Preparations industry Syros Pharmaceuticals Inc achieved highest sequential Income from Cont. Operations growth. While Syros Pharmaceuticals Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SYRS's I. Quarter Q/Q Income from Cont. Operations Comment
I. Quarter 2023 results of -23.79 millions by Syros Pharmaceuticals Inc come out even worse if you take a look at loss from continued operations -4.77 millions a quarter before.

Within Major Pharmaceutical Preparations industry Syros Pharmaceuticals Inc achieved highest sequential Income from Cont. Operations growth. While Syros Pharmaceuticals Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Syros Pharmaceuticals Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)
Cumulative Income from Cont. Operations 12 Months Ending $ -93.30 $ -94.65 $ -113.69 $ -109.47 $ -97.48
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #

New: More SYRS's historic Income from Cont. Operations Growth >>



Cumulative Income from Cont. Operations growth Comment


Syros Pharmaceuticals Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment


Syros Pharmaceuticals Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
SYRS's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for SYRS's Competitors
Income from Cont. Operations Growth for Syros Pharmaceuticals Inc 's Suppliers
Income from Cont. Operations Growth for SYRS's Customers

You may also want to know
SYRS's Annual Growth Rates SYRS's Profitability Ratios SYRS's Asset Turnover Ratio SYRS's Dividend Growth
SYRS's Roe SYRS's Valuation Ratios SYRS's Financial Strength Ratios SYRS's Dividend Payout Ratio
SYRS's Roa SYRS's Inventory Turnover Ratio SYRS's Growth Rates SYRS's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Mar 31 2023 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Mar 31 2023
Intuitive Surgical Inc -2.33%$ -2.328 millions
U S Physical Therapy Inc-4.63%$ -4.632 millions
Zoetis Inc -7.24%$ -7.239 millions
Innoviva Inc -7.91%$ -7.906 millions
Vertex Pharmaceuticals Inc-8.17%$ -8.175 millions
Edwards Lifesciences Corporation-8.86%$ -8.860 millions
Lifevantage Corp-10.43%$ -10.429 millions
Iqvia Holdings Inc -11.08%$ -11.077 millions
Viemed Healthcare Inc -13.90%$ -13.905 millions
Insulet Corporation-14.39%$ -14.388 millions
Chemed Corporation-15.66%$ -15.659 millions
Regeneron Pharmaceuticals Inc -15.99%$ -15.994 millions
Davita Inc -17.04%$ -17.038 millions
National Research Corporation-18.44%$ -18.445 millions
West Pharmaceutical Services Inc -19.45%$ -19.448 millions
Amedisys Inc-21.45%$ -21.455 millions
Dariohealth Corp -21.64%$ -21.641 millions
Biomx Inc -22.13%$ -22.132 millions
3m Company-24.71%$ -24.712 millions
Integra Lifesciences Holdings Corp-26.37%$ -26.367 millions
National Healthcare Corp-26.48%$ -26.477 millions
Eli Lilly And Company-29.32%$ -29.324 millions
Pacific Health Care Organization Inc -30.46%$ -30.459 millions
Corcept Therapeutics Inc-30.66%$ -30.662 millions
Synaptogenix Inc -31.54%$ -31.544 millions
Supernus Pharmaceuticals inc -33.84%$ -33.838 millions
Halozyme Therapeutics Inc -34.09%$ -34.094 millions
Align Technology inc -34.62%$ -34.624 millions
Avantor Inc -36.19%$ -36.187 millions
Baxter International Inc -38.36%$ -38.356 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071